Drugs / EB-NK-MF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07617753 | Mar 2026 → Jun 2027 expected | fallopian tube carcinoma, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Beijing Biotech | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EB-NK-MF | “EB-NK-MF CAR-NK cells (dose levels 1-3)” NCT07617753 ↗ |
| Modality | Cell therapy | “dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells” NCT07617753 ↗ |
| Route | Other | “given intraperitoneally” NCT07617753 ↗ |
| Target | FOLR1 | “Directed Against Mesothelin (MSLN), Folate Receptor Alpha (FRα/FOLR1), and/or MUC16” NCT07617753 ↗ |
| Target | MSLN | “Directed Against Mesothelin (MSLN), Folate Receptor Alpha (FRα/FOLR1), and/or MUC16” NCT07617753 ↗ |
| Target | MUC16 | “Directed Against Mesothelin (MSLN), Folate Receptor Alpha (FRα/FOLR1), and/or MUC16” NCT07617753 ↗ |